Tildrakizumab

A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis

Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis

Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis

Observational Study of Tildrakizumab in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

MIcrovascular dysfuNction In Moderate-severe Psoriasis

Tilrdakizumab Almirall

Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease

A Study to Assess Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting

Observational Real-world Evidence (RWE) Study to Assess Patient-reported Wellbeing Using Tildrakizumab in Live Setting - POSITIVE Study

A Study of Tildrakizumab in the Treatment of Genital Psoriasis (CZATCH-Genital-PsO)

A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis

Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo

Effects of Tildrakizumab on Epigenetic Age

Predicting Inflammatory Skin Disease Response to IL-23 Blockade

Abiraterone Acetate in Combination With Tildrakizumab

Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy

Long-Term Treatment Effect With Tildrakizumab in Participants With Plaque Psoriasis

A Study to Determine the Optimal Dose of Tildrakizumab (SCH 900222/MK-3222) for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495) (MK-3222-003)